GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Interest Expense

Sandoz Group AG (Sandoz Group AG) Interest Expense : $ Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sandoz Group AG's interest expense for the three months ended in Dec. 2023 was $ -202 Mil. Sandoz Group AG does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Dec. 2023.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sandoz Group AG's Operating Income for the three months ended in Dec. 2023 was $ 375 Mil. Sandoz Group AG's Interest Expense for the three months ended in Dec. 2023 was $ -202 Mil. Sandoz Group AG's Interest Coverage for the quarter that ended in Dec. 2023 was 1.86. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Sandoz Group AG Interest Expense Historical Data

The historical data trend for Sandoz Group AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Interest Expense Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Interest Expense
-89.00 -202.00

Sandoz Group AG Quarterly Data
Dec22 Dec23
Interest Expense -89.00 -202.00

Sandoz Group AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.


Sandoz Group AG  (OTCPK:SDZNY) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sandoz Group AG's Interest Expense for the three months ended in Dec. 2023 was $-202 Mil. Its Operating Income for the three months ended in Dec. 2023 was $375 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $4,230 Mil.

Sandoz Group AG's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*375/-202
=1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024